Global Canine Tumor Screening Market Growth (Status and Outlook) 2026-2032

The global Canine Tumor Screening market size is predicted to grow from US$ 426 million in 2025 to US$ 666 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.

Canine liquid biopsy is a method of analyzing biomarkers in body fluids (such as blood, urine or saliva) to detect the presence of cancer or monitor the progression of cancer. Unlike traditional tissue biopsies, liquid biopsies are non-invasive, fast and convenient. By obtaining a small blood sample, doctors can analyze free DNA, circulating tumor cells, exosomes, etc. to obtain information about the tumor.

United States market for Canine Tumor Screening is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Canine Tumor Screening is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Canine Tumor Screening is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Canine Tumor Screening players cover PetDx, CYTOGEN, BioChain, Small Door, ANGLE, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “Canine Tumor Screening Industry Forecast” looks at past sales and reviews total world Canine Tumor Screening sales in 2025, providing a comprehensive analysis by region and market sector of projected Canine Tumor Screening sales for 2026 through 2032. With Canine Tumor Screening sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Canine Tumor Screening industry.

This Insight Report provides a comprehensive analysis of the global Canine Tumor Screening landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Canine Tumor Screening portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Canine Tumor Screening market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Canine Tumor Screening and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Canine Tumor Screening.

This report presents a comprehensive overview, market shares, and growth opportunities of Canine Tumor Screening market by product type, application, key players and key regions and countries.

Segmentation by Type:
Cut Biopsy
Needle Biopsy

Segmentation by Application:
Pet Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
PetDx
CYTOGEN
BioChain
Small Door
ANGLE
BioChain Institute Inc.
CANCAN DIAGNOSTICS.

Please note: The report will take approximately 2 business days to prepare and deliver. Show more